TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07461220: A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants With Parkinson's Disease and Apathy

Sponsor: Integrative Research Laboratories AB · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 75 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,266,200

Rescue Site Savings

+$4,122,500

Unlock Full NCT07461220 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07461220 Rescue Dossier →